|
 Merck, the maker of MS drug Rebif, said on Tuesday the project did
"not meet Merck's threshold for continued investment".
Merck bought worldwide exclusive license rights from Ono for the
development and commercialization of ceralifimod outside of Japan,
Korea and Taiwan in October 2011.
The drug candidate is currently in the second of three phases
typically required for regulatory approval.
(Reporting by Ludwig Burger; Editing by Christoph Steitz)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
